AstraZeneca traded at 12,824.00 this Friday October 23rd, decreasing 156.00 or 1.20 percent since the previous trading session. Looking back, over the last four weeks, AstraZeneca lost 3.42 percent. Over the last 12 months, its price rose by 2.33 percent. Looking ahead, we forecast AstraZeneca to be priced at 12,573.93 by the end of this quarter and at 11,852.61 in one year, according to Trading Economics global macro models projections and analysts expectations.
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.